Stockreport

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals [Yahoo! Finance]

OS Therapies Incorporated  (OSTX) 
PDF 8 pre-clinical immunotherapy candidates targeting 30+ cancers added NEW YORK, April 09, 2025 BUSINESS WIRE )--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Comp [Read more]